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The local application of controlled hypobaric stress represents a novel means to facilitate drug delivery into the
skin. The aims of this work were to understand how hypobaric stress modiﬁed the properties of the skin and as-
sess if this penetration enhancement strategy could improve the percutaneous penetration of a macromolecule.
Measurements of skin thickness demonstrated that the topical application of hypobaric stress thinned the tissue
(p b 0.05), atomic forcemicroscopy showed that it shrunk the corneocytes in the stratum corneum (p b 0.001) and
the imaging of the skin hair follicles usingmultiphotonmicroscopy showed that it opened the follicular infundib-
ula (p b 0.001). Together, these changes contributed to a 19.6-fold increase in in vitro percutaneous penetration of
a 10,000 molecular weight dextran molecule, which was shown using ﬂuorescence microscopy to be localized
around the hair follicles, when applied to the skin using hypobaric stress. In vivo, in the rat, a local hemodynamic
response (i.e. a signiﬁcant increase in blood ﬂow, p b 0.001) was shown to contribute to the increase in follicular
transport of the dextran to produce a systemic absorption of 7.2± 2.81 fg·mL−1. When hypobaric stresswas not
applied to the rat there was no detectable absorption of dextran and this provided evidence that this novel
penetration enhancement technique can improve the percutaneous penetration of macromolecules after topical
application to the skin.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
The delivery of macromolecules such as peptides, proteins and anti-
bodies via the skin is an attractive proposal when considering the treat-
ment and prevention of diseases. However, their administration via this
route is a challenge due to the skin's highly stratiﬁed structure [1,2]. The
stratum corneum and the multiple underlying layers, which constitute
the cutaneous tissue, exhibit highly selective permeability that only al-
lows the rapid absorption of relatively small, lipophilic compounds to
enter the body after topical administration (b500 Da, Log P 0.8–3) [3,4].
Therefore, the only means by which macromolecules can enter the skin
tissue at a rate that is suitable for therapeutic applications is by the use
of a penetration enhancement strategy [5–9]. While many of the devel-
oped approaches to allow macromolecules into the skin are effective
they each have associated cost, compliance and safety issues that make
their use limited in clinical practice [10]. There therefore remains a need
to develop new technologies to facilitate the passage of high molecular
weight therapeutic agents into the skin.
The few documented reports that have assessed the capability of ap-
plying local hypobaric stress to alter the properties of the skin suggest
that it could represent a novelmeans to enhance drug percutaneous pen-
etration. For example, the application of local hypobaric stress has been
documented to signiﬁcantly increased transepidermal water loss
(TEWL) and decrease the stratum corneum's water content [11]. These ef-
fects could potentially thin the skin and facilitate drug entry. In addition,
the hypobaric stress induced stretching of the skin has been shown to
cause disorganization of the intercellular lipid bilayers and rupture of
the skin's corneosomes [12,13]. Increasing the lipid ﬂuidity is a mecha-
nism that chemical penetration enhancers use to increase percutaneous
penetration and therefore this could be an important means by which
hypobaric stress could act to enhance percutaneous penetration. Further-
more, the continuous application of localized sub-atmospheric pressures
has been reported to signiﬁcantly increase cutaneous blood ﬂow [14,
15]. Increasing the blood ﬂow under local hypobaric stress conditions
may increase the systemic absorption of topically applied agents due to
the dilation of the dermal blood vessels and their displacement towards
the skin surface [16]. However, howthese effects of hypobaric stress inﬂu-
ence skin penetration of macromolecules is currently unknown.
The purpose of the present studywas to assess the inﬂuence of local-
ly applied hypobaric stress upon the mechanical and physiological
properties of cutaneous tissue and then using this knowledge test if
hypobaric stress could enhance the percutaneous penetration ofmacro-
molecules. To apply controlled hypobaric stress to the skin one of the
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most widely used test systems for studying skin permeability, the Franz
diffusion cell, was adapted to operate at a sub-atmospheric pressure of
500mBar. A series of ﬂuorescein isothiocyanate (FITC)-labeled dextrans
was used as the model macromolecules for this work because of their
molecular homogeneity, their excellent chemical and physical stability,
their commercial availability and their ability to be tracked in vitro and
in vivo [17]. In vitro permeation studies were performed using rat skin.
It is accepted that rat skin is more permeable compared to human
skin, but this membrane was selected primarily because this allowed
similar studies to be performed in vitro and in vivo. In addition, the rat
was easily amenable to the measurement of blood ﬂow using full-ﬁeld
laser perfusion imaging (FLPI) and systemic bioavailability using stan-
dard blood sampling protocols [18–20]. Porcine skin was also utilized
as a permeation barrier to explore the transdermal transport mecha-
nism of the macromolecules because it is the most relevant animal
model for human skin [18]. In addition, this barrier is especially suitable
for studying follicular structures as the ear cartilage prevents contrac-
tion of tensile ﬁbres and closure of follicles upon sample preparation,
which can occur with human and rat skin [21]. The changes in the
skin caused by the application of hypobaric stress were assessed using
multiphotonmicroscopy, lightmicroscopy and atomic forcemicroscop-
ic (AFM) imaging. In addition, the entry of the dextran into the cutane-
ous tissue was followed using ﬂuorescence microscopy to try and
elucidate the route of entry of this molecule into the skin.
2. Materials and methods
2.1. Materials
Acetonitrile andmethanol bothHPLC grade, DPXmountingmedium,
xylene and Optiphase scintisafe gel were purchased from Fischer Scien-
tiﬁc (Leicester, UK). Tetracaine base BP grade (99.9%), formalin solution
neutral buffer 10%, DAPI medium, ethanol, heparin sodium salt (I-A),
urethane, 0.7% glacial acetic acid, isopropanol and FTIC-dextran with
average molecular weight (Mw) of 4 kDa (FD-4) and 10 kDa (FD-10S)
used without any further puriﬁcation steps were supplied by Sigma Al-
drich (Dorset, UK). Concentrated hydrochloric acid and sodiumhydrox-
ide was from Fluka (Dorset, UK). Sodium acetate was provided by
Alfa Aesar (Heysham, UK). Silicone membranes with a thickness of
0.25mmwere purchased fromGBUKHealthcare (Selby, UK). Phosphate
buffered saline (Dulbecco A) tablets were obtained from Oxiod Limited
(Hampshire, England). The Tissue-Tek®O.C.T™ compound, scintillation
vials and hydrogen peroxide 30%were obtained fromVWR Internation-
al (Leicestershire, UK). Dextran (carboxyl-14C) with an average M.W. of
10 kDa and speciﬁc activity of 0.00006 Ci/mmol was obtained from
American Radiolabeled Chemicals, Inc. (St. Louis, USA). Soluene® 350
was provided by Perkin Elmer (Bucks, UK). Isoﬂurane 100% (w/v) inha-
lation vapour liquid was obtained from Animal Care Ltd. (York, UK).
2.2. Animals
All procedures were conducted in accordance with the UK Animal
Scientiﬁc Procedures Act (1986) and Amendments Regulations (2012)
and approved by the King’s College London Animal Welfare and Ethical
Review Body. Sprague Dawley male rats (6–9 weeks old, ca. 220–250 g;
Charles River, Kent, UK) were caged in groups of 4 with free access to
water and food. A temperature of 19–22 °C was maintained, with a rel-
ative humidity of 45–65%, and a 12 h light/dark cycle. Animals were ac-
climatized for 7 days before each experiment.
2.3. In vitro dextran permeation studies
Rats were killed by intraperitoneal injection of sodium pentobarbital.
The dorsal hair was removed using an animal hair clipper and full thick-
ness skin was excised. The excess fat adhering to the dermis side was
removed carefully with a scalpel. A standard Franz diffusion cell was
attached to an in-house designed aluminium support frame (Supplemen-
tary data Fig. S1a, b and c) that was able to pressure seal the donor com-
partment (Supplementary data Fig. S1d). To develop a sound
experimental protocol using the assembled pressure cell set up, a series
of transport experiments with porcine skin were conducted. These pre-
liminary studies indicated that the receiver chamber of the Franz cell
could not be ﬁlled with a liquid because the hypobaric pressure caused
suction of the liquid from the donor phase into the receiver compartment.
As a consequence, the traditional Franz cell was adapted to use a sponge
in order to collect the drug exiting the dermal side of the skin. The sponge
was shown to remain in contact with the skin through the experiments
and it allowed the complete recovery of the drug that had passed through
the skin (Supplementary data Fig. S2). For the in vitro dextran permeation
studies (note: ﬂuorescein isothiocyanate (FITC)-dextran was used
throughout the in vitro section of work), rat skin was employed using
the permeation methodology developed with the porcine skin. The
depilated rat skinharvested from the animalswas cut into pieces of a suit-
able size and mounted with the stratum corneum facing the donor com-
partment in the Franz diffusion cell (University of Southampton, UK).
The pressure cell sealed donor compartment was attached to the Franz
cell base and each diffusion cell was placed on a submersible stirring
plate in a pre-heated water bath (Grant Instruments, Cambridge, UK)
set at 37 °C, to obtain a temperature of 32 °C at the membrane surface
[22]. The sealing of the cells was evaluated by their resistance to air re-
moval and the absence of signiﬁcant solvent back diffusion into the
donor compartment prior to the application of hypobaric pressure. Any
leaking cells were not used in the experiments and hence all the data
was used in the data analysis. The experiments were initiated by the ap-
plication of 1mL of a donor solution (containing either 125 μMof FD-4 or
FD-10S in phosphate buffer solution at pH 7.4) to the apical surface of the
skin. Permeation experiments were conducted under atmospheric
(1010 mBar) and hypobaric pressure (500 mBar) for 1 h using the pres-
sure cell assembly. The hypobaric conditions had previously been tested
in a pilot study and it appeared to cause no skin blistering (data not
shown), but this was investigated further using skin histology (detailed
in a subsequent section). The hypobaric pressure was applied to the
skin immediately after the application of the donor solution by the re-
moval of air from the Franz cell donor compartment, which was sealed
onto the skin and thus acted as a vacuum chamber. A manometer was
mounted on the donor compartment in order to record the pressure ap-
plied. Hypobaric stress was applied for 1 h and any small loss in pressure
was corrected by extracting further air from the Franz cell. After the 1 h
time period of hypobaric stress the cells were allowed to equilibrate at at-
mospheric pressure and the permeation experiments were continued for
a total of 20 h to allow suitable drug levels to accumulate in the skin to fa-
cilitate accurate analytical quantiﬁcation. At the end of the transport stud-
ies the stratum corneumwas removed by tape stripping (ca. 20 strips until
the skinwas translucent) using adhesive tape (Scotch 845 book tape, 3M,
Bracknell, UK) and the epidermis was separated from the dermis as pre-
viously described [23]. Dextranwas extracted from the receptor compart-
ment, adhesive tape and skin using a phosphate buffer saline (pH 7.4)
extraction solution. The dextran was quantiﬁed using a stand-alone ﬂuo-
rescence spectrometer (Varian Cary Eclipse ﬂuorescence spectrophotom-
eter, Agilent, Cheadle, UK) at an excitation wavelength of 495 nm and
ﬂuorescent emission wavelength of 515 nm. The assay was veriﬁed as
‘ﬁt for purpose’ by determination of linearity, precision and sensitivity
(data not shown). Drug extraction was within the 100 ± 15% recovery
rates published in guidelines [24]. The effect of local hypobaric stress
upon dextran cutaneous bioavailability was represented as an enhance-
ment ratio (ER), which was calculated according to Eq. (1) where CP
and CATwere the amount of dextran (μg) per cm2 of skin under hypobaric
and atmospheric pressure conditions, respectively.
ER ¼ CP
CAT
: ð1Þ
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2.4. Fluorescence microscopy
The skin samples remaining after the completion of the (FITC)-dex-
tran transport studieswere subject to ﬂuorescencemicroscopy analysis.
To perform the analysis the skin samples were prepared by cutting
them in half along their diameter and embedding them in O.C.T. com-
pound. The embedded samples were sectioned in 20 μm slices using a
cryostat microtome (Bright Instruments, Huntingdon, UK). The skin
sections were mounted, stained with DAPI and covered with glass
cover slips. Fluorescence photomicrographs were obtained with a
Zeiss Axioscope microscope equipped with a Nikon Digital Camera
(DXM1200; Nikon, Kingston upon Thames, UK) at a magniﬁcation of
10×. Images were acquired using two ﬂuorescence channels to allow
the visualization of the cellular structures stained by DAPI (blue colour
emission ~460 nm) and the FITC-dextran ﬂuorescence signal (green
colour emission ~520 nm). Tissue samples without FITC-dextran were
also tested as controls. Images were processed using Image J Software
(National Institutes of Health, Maryland, USA).
2.5. Skin morphology and physiology
2.5.1. Multiphoton ﬂuorescence microscopy analysis
Multiphoton microscope images were taken using a custom built
system developed around a FN1 upright microscope (Nikon Instru-
ments, Melville, USA). The excitation source was a femtosecond pulsed
Titanium:sapphire Chameleon Vision S laser (Coherent Inc., Santa Clara,
USA) tuned to 800 nm, which was relayed into an afocal galvanometer
scanning system. This was then projected onto the back aperture of an
inﬁnity corrected Nikon air-objective (NA. 0.5 × 20; Nikon Instruments,
Melville, USA), where it was focused on the sample. The emitted ﬂuo-
rescence was collected onto two detection channels housed in a non-
descanned conﬁguration, with bandpass ﬁlters of 525 ± 30 nm and
593± 40 nm, respectively. The detectors used were a HPM-100-50 Hy-
brid Photomultiplier Tubes (PMTs) (Becker & Hickl, Berlin, Germany)
operating in single photon counting mode. The microscope was con-
trolled by a software developed using the graphical based LabVIEWpro-
gramming language (National Instruments Corporation, Austin, USA).
For these experiments porcine skin was challenged under hypobaric
pressure conditions employed in the permeation studies in order to
try and retain the follicular structure (Supplementary data Fig. S2). Por-
cine skin was used to develop the hypobaricmodel and it was shown to
behave in a very similar manner to rat skin upon the application of
hypobaric pressure using a number of different tests in this work (see
Fig. S3 for an example). After hypobaric treatment, the stressed skin
was immediately mounted on a glass slide with the stratum corneum
facing the objective. Z stacks of the porcine skin samples were acquired
using Bio-Rad software (Philadelphia, USA) and were taken from the
stratum corneum to the dermis (1–100 μm deep), with 2 μm steps.
Two dimensional images were generated by raster scanning the excita-
tion beam across the skin sample utilizing the afocal scanning system.
Measurements of the hair follicle infundibula were performed using
in-house developed software allowing the assessment of the length
and depth of the follicular structures.
2.5.2. Atomic force microscopy analysis
Corneocytes were collected from the porcine skin surface (n = 6),
treated under the same hypobaric stress conditions employed in the
permeation studies, by the removal of 4, 6 and 10 tape strips from the
same cutaneous site. Porcine skin was used in the AFM studies because
it allowed the collection of single corneocytes, which was required for
the imaging. This method had been previously described by Fredonnet
et al. [25]. The tape with the collected corneocytes was then ﬁxed on a
glass slide and images were obtained from a Nanoscope V multimode
scanning atomic force microscope (Digital Instruments, Coventry,
Bresso, ItalyUK). Imaging was performed in tapping mode in air. Alu-
minium coated Si3N4 cantilevers with integrated pyramidal tips
(NSC15/Al, MikroMasch, Wetzlar, Germany) with a reported resonance
frequency of 325 kHz and a spring constant of 40 N/m were used. After
acquisition, the images were ﬂattened and analysed using section anal-
ysis with the Gwyddion software (Czech Metrology Institute, Brno,
Czech Republic). The cell outlines were clearly visible from the comput-
er display and this allowed the cells size to be determined using the
AFM software.
2.5.3. Histological studies
Skin samples, challenged under the same hypobaric stress condi-
tions employed in the permeation studies, were cut into small pieces
and ﬁxed with 10% neutral-buffered formalin for 24 h at room tem-
perature. Both porcine and rat skin samples were used in these stud-
ies. These samples were subsequently embedded in O.C.T. [26].
Cross-section slices of 20 μm thickness were obtained using a Bright
Model OTF cryostat (Bright Instruments, Huntingdon, UK). The sam-
ples were stained following the Ellis Haematoxylin and Eosin (H&E)
staining protocol [27] and dehydrated with different volumes of eth-
anol (75%, 95%, and 100%) and xylene for 5 min each, before being
mounted in DPX and covered with glass cover slips. The samples
were analysed using a Leica DM 200 Led light microscope
(Leica Microsystems, Wetzlar, Germany) equipped with a Leica
digital camera (Model DFC 295) at a magniﬁcation of 4× and 40×.
Images were processed using Las v4.4 Imaging Software (Leica
Microsystems, Wetzlar, Germany).
2.6. Cutaneous blood ﬂow measurements
Rats were anaesthetized by inhalation of (~2%) isoﬂurane/(~2%)
O2 and cutaneous blood ﬂow was assessed in the whole plantar
hind paw area using the Full-Field Laser Perfusion Imager (FLPI,
Moor Instruments, Axminster, UK). Baseline blood ﬂow in both
hind paws was recorded prior to the application of hypobaric stress
to ensure the hemodynamic vascular responses were stabilized fol-
lowing the induction of anaesthesia. The ipsilateral hind paw was
subsequently exposed to 500 mBar of hypobaric stress for 7 min
(n = 6) using the same adapted pressure cell described for the
in vitro permeation studies, but without the receiver compartment
as the cell was placed directly onto the rat's hind paw. The pressure
cell application time was reduced to 7 min in the in vivo studies be-
cause this was the minimum time that was shown in pilot studies
to change blood ﬂow. The contralateral paw was untreated and
served as a control. Changes in blood ﬂow after hypobaric stress
treatment were followed for 15 min. The rats were placed on a
heating mat (Harvard Apparatus, Cambridge, UK) in the ventral po-
sition maintained at 36 °C for blood ﬂow measurements. All animals
were culled upon termination of the experiment. Results were
expressed as a measure of % change in blood ﬂow from baseline.
Eq. (2) was used to drive % change in blood ﬂow and Eq. (3) was
used to calculate the maximum vasodilatation.
%Change in blood flow ¼ Blood flow Baselineð Þ
Baseline
 100 ð2Þ
Maximum vasodilatation ¼ Peak vasodilatation Baselineð Þ
Baseline
 100: ð3Þ
2.7. Pharmacokinetic studies
Animals were anaesthetized by intraperitoneal injection of urethane
(0.175 g/100 g) and placed on a heatingmat (Harvard Apparatus, Cam-
bridge, UK) in the ventral position maintained at 36 °C for the duration
of the experiments. The dorsal fur was carefully removed with an ani-
mal hair clipper and the donor compartment of a Franz cell with an
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available area of 2.1 ± 0.2 cm2 was attached to the shaved skin with
glue [28]. Rats were bled by tail veil puncture and ca. 100 μL of blood
was collected in a heparinized tube. To initiate the permeation studies
a 300 μL aliquot of 14C-labeled dextran in phosphate buffer (0.79 μCi
equivalent to 1.428 pM) was added to the donor compartment of the
Franz cell. Permeation studieswere conducted under atmospheric pres-
sure (1010 mBar) and hypobaric pressure (500 mBar) for 7 h (n= 5).
To apply the hypobaric pressure the pressure cell assembly was at-
tached to the top of the Franz cell donor compartment and a sub-
atmospheric pressure of 500 mBar was applied for the ﬁrst hour (n=
5) of the experimental period. At hourly time points for 7 h, the rats
were bled by tail vein puncture and ca. 100 μL of blood was collected
to a heparinized tube. Blood withdrawn did not exceed 10% of the
6.86 ± 0.53 mL/100 g rat blood volume per day [29]. All animals were
culled upon termination of the experiment. Blood samples were trans-
ferred to 20 mL scintillation vials, 1 mL of tissue solubilizer was added
and the sampleswere shaken overnight at 55 °C. Before adding the scin-
tillation cocktail, samples were decolorized by adding 0.3 mL of 30%
H2O2 and isopropanol as an antifoaming agent. Samples were subse-
quently shaken at 55 °C for at least 3 h to expel H2O2 content and then
mixed with 20 mL of undiluted scintillation cocktail acidiﬁed with gla-
cial acetic acid to eliminate any chemiluminescence. The samples
were stored in the dark for 24 h before counting [30]. 14C radioactivity
was quantiﬁed for each sample using a LS6500 multi-purpose scintilla-
tion counter (Beckman Coulter, Brea, USA)with a deﬁned limit of detec-
tion of 3 × background level measurements. Total radioactivity in the
blood was calculated based on the total blood volume of 6.86 ±
0.53 ml/100 g previously reported for Sprague Dawley male rats [29].
The results were expressed as amount of 14C-dextran (fg) per mL of
blood.
2.8. Cutaneous bioavailability and tissue distribution
At the end of the transport studies (Section 2.3), the dorsal skin
underneath the Franz cell donor compartment and organs (heart,
bladder, kidneys, liver and spleen) were collected, rinsed with dis-
tilled water and weighed. The stratum corneum was removed by
tape stripping [23] and the adhesive strips were dissolved in 15 mL
of tissue solubilizer and left at room temperature for 2 days [31]. A
2 mL aliquot of the tissue extraction solution was then transferred
to 20 mL scintillation vials and mixed with 15 mL of scintillation
cocktail, acidiﬁed with glacial acetic acid, to eliminate any chemilu-
minescence [30]. The stripped skin and whole organs were homoge-
nized using a tissue homogenizer (Ultra Turrax, Fisher Scientiﬁc,
Leicester, UK) in phosphate buffer (0.2 mL per 100 mg of tissue). A
200 μL aliquot of the homogenized solution was transferred using a
positive displacement pipette to 20 mL scintillation vials, 1 mL of tis-
sue solubilizer was added and the samples were shaken overnight at
55 °C. The radioactivity of the samples was determined as described
above. Drug extraction was within the 100 ± 15% recovery rates,
which was in line with published regulatory guidelines [24]. The re-
sults were expressed as amount of 14C-dextran (fM) per cm2 or per g
of tissue (n = 5). The effect of local hypobaric stress upon 14C-
labeled dextran cutaneous bioavailability and organ uptake was
represented by an enhancement ratio (ER) which was calculated
according to Eq. (1).
2.9. Statistical analysis
Statistical evaluationwas carried out using the Statistical Package for
the Social Sciences software (SPSs version 16.0, SPSS Inc., Chicago, USA).
Data were checked in terms of normality (Kolmogorov–Smirnov test)
and homogeneity of variances (Levene's test) prior to analysis. Statisti-
cal comparison was performed using Student's t-test and a statistically
signiﬁcant difference was deﬁned as when p b 0.05 and denoted as:
*p b 0.05, **p b 0.01 and ***p b 0.001.
3. Results and discussion
3.1. In vitro effects of local hypobaric stress
The application of topical hypobaric stress altered the skin deposi-
tion of both FD-4 and FD-10S (Fig. 1a). However, the different sized dex-
tranmolecules showed a different skin deposition proﬁle in response to
the application of hypobaric stress. For example, the FD-4 dextran dem-
onstrated a 3-fold greater deposition within the dermal tissue whereas,
the amount of FD-10S retained in the dermal tissue was found to be
equivalent (p b 0.05) under both permeation conditions (Fig. 1b). The
transdermal delivery of both FDs was found to be signiﬁcantly greater
(p b 0.01) when compared to atmospheric conditions (2.9 and 19.6-
fold increase, respectively) (Fig. 1). However, calculating the enhance-
ment ratios showed that the effect of hypobaric stress was more pro-
nounced upon the transdermal delivery of the higher molecular
weight dextran (10 kDa).
The change in dextran skin deposition proﬁles upon the application of
hypobaric stress recorded in this study was not thought to be inﬂuenced
by chemical degradation since it has been previously shown that FDs, of
various molecular weights, were chemically stable after the permeation
across rat skin under similar experimental conditions [32]. Therefore,
the change in how dextran deposited in the skin was thought to be con-
sequence of themanner inwhich the hypobaric stress altered the proper-
ties of the tissue. Molecules with a molecular weight of N1000 ﬁnd it
Fig. 1. Permeation of FD-4 (a) and FD-10S (b) into rat skin under atmospheric (1010mBar) and hypobaric conditions (500mBar). Each point representsmean± standard deviation (n=4) for
atmospheric conditions and (n = 5) for hypobaric conditions. ER (Enhancement Ratio) represents the ratio between the amount of drug in the tissue under hypobaric and atmospheric
conditions. Student's t-test with **p b 0.01 and ***p b 0.001.
69R. Inacio et al. / Journal of Controlled Release 226 (2016) 66–76
problematic to pass through the skin passively via the inter or intracellu-
lar pathways [33]. Previously, permeation studies using FDs through rat
skin, porcine skin and in vitro cultured human epidermis models have
suggested that the follicular route is the primary permeation pathway
for dextrans with a size between 4 and 10 kDa [33–35]. This was recently
conﬁrmed in a novel follicle-plugging method, which showed that the
permeation of FD-4was signiﬁcantly inﬂuenced by the availability of “un-
plugged”hair follicles [36]. Therefore, the permeation datawas thought to
show the manner in which the hypobaric stress had modiﬁed the
transfollicular route of transport into the skin. The superior enhancement
of the FD-10S compared to the FD-4 by hypobaric stress supported this
hypothesis as the former was more likely to be transported mainly
through the follicular route. However, it was thought necessary to inves-
tigate this result further by trying to determine how these molecules en-
tered the skin using ﬂuorescence microscopy.
The FITC-derived ﬂuorescence signal appeared to be much more in-
tense in deeper skin layers exposed to hypobaric treatment (Fig. 2d and
f) compared to the samples under atmospheric conditions (Fig. 2c and
e). The ﬂuorescence signals were most concentrated around the
perifollicular region for both (FITC)-dextrans, which suggested that
hypobaric treatment inﬂuenced drug transport across the hair follicle
structures. However, the two different molecular weight dextrans did
show different skin deposition proﬁles upon the application of
hypobaric pressure. The lower molecular weight FD dextran gave a
broad and continuous spatial distribution of the ﬂuorescence signal
that extended from the stratum corneum into deeper layers of the skin
(Fig. 2d). This implied that the FD-4 dextran was transported into the
skin not only through the follicular route, but also to some extent by
inter and intra cellular passive diffusion. The FD-10S only appeared in
the deeper tissue layers around the perifollicular region, suggesting
Fig. 2. Fluorescence microscopic examination after topical administration of FD-4 and FD-10S dextran under atmospheric conditions (1010 mBar) and hypobaric stress conditions
(500 mBar): control samples at atmospheric (a) and after hypobaric treatment (b); topical FD-4 delivery under atmospheric conditions (c) and upon hypobaric stress treatment (d);
topical FD-10S delivery under atmospheric conditions (e) and upon hypobaric stress treatment (f). Green: FITC, blue: DAPI. Original magniﬁcation × 10. SC, stratum corneum; E,
epidermis and D, dermis.
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that the follicular pathwaywas themain route utilized by this molecule
to penetrate into the hypobaric stressed skin. The green ﬁlter autoﬂuo-
rescence observed from the control samples, where no FITC-dextran
had been applied (Fig. 2a and b), was minimal compared to signal
from samples treatedwith FITC-dextran [37]. Therefore, it was conclud-
ed from theﬂorescencemicroscopy studies that the FITC-dextrans were
being primarily transported by the follicular route. This supported the
transport data despite there being evidence of some FD-4 passive trans-
port through the stratum corneum. However, this data did not demon-
strate howhypobaric pressuremodiﬁed the hair follicle structure and so
multiphoton microscopy was employed to try and investigate this as-
pect in subsequent experiments. The multiphoton microscopy images
of the hair follicles showed that follicular infundibula of the hypobaric
stressed skin were signiﬁcantly wider (p b 0.001) than the untreated
skin. An average horizontal planner length of 243± 23.9 μmwas record-
ed after hypobaric pressure treatment compared to 151 ± 40.5 μm after
identical sample treatment under atmospheric conditions (Fig. 3c and
f). There was also a signiﬁcant decrease (p b 0.01) in the depth of the fol-
licular structures after the application of hypobaric stress (159± 14.5 μm
— hypobaric pressure vs. 190± 30.1 μm— atmospheric pressure) (Fig. 3c
and f). This greater horizontal planner length of the follicular infundibula
with the concomitant decrease in the depth of the follicular structurewas
Fig. 3.Multiphoton microscopic images of porcine follicular infundibula. a) 3D reconstruction under atmospheric conditions (1010 mBar), b) top view (singe Z-stack cross-section at
1010 mBar), c) side view at 1010 mBar with an average length of 151 ± 40.5 μm and depth of 190 ± 30.1 μm, d) 3D reconstruction after applying hypobaric pressure (500 mBar),
e) top view after hypobaric pressure (Z-stack cross-section), f) side view after hypobaric pressure with an average length of 243 ± 23.9 μm and depth of 159 ± 14.5 μm.
Fig. 4. Atomic force microscopy analysis of in vitro porcine skin corneocytes at
a) atmospheric conditions (1010 mBar) with average length of 41.5 ± 5.5 μm and width
of 37.2 ± 7.2 μm and b) within 25 min of applying hypobaric pressure (500 mBar) with
average length of 31.5 ± 8.2 μm and width of 26.2 ± 6.8 μm.
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believed to be due to the stretching of the skin when subjected to
hypobaric stress (Supplementary data Fig. S3b). Previous studies have
suggested that the application of hypobaric pressure can be used to
‘open’ hair follicles [38] and this opening up of the follicles, which have
been shown to be only partially accessible to drug permeation in their na-
tive state [39–41], was considered to be a major factor in facilitating the
macromolecule percutaneous penetration when hypobaric pressure was
applied to the skin in the current work. This did not however explain
the increased passive inter and intracellular diffusion observed with the
4 kDa dextran and hence AFM was used to investigate the corneocytes
of the stratum corneum.
The AFM studies demonstrated that the average size of the por-
cine corneocytes was signiﬁcantly smaller upon hypobaric treatment
(Fig. 4). They displayed a length and width of 31.5 ± 8.2 μm and
26.2 ± 6.8 μm under hypobaric conditions vs. 41.5 ± 5.5 μm and
37.2 ± 7.2 μm under atmospheric conditions respectively
(p b 0.001, n = 20). The barrier characteristics of the skin are inﬂu-
enced by the properties of the lipids and the path-length for diffu-
sion. The latter depends on the number of corneocytes, their
cohesion and their size. Previously, a reduction in the corneocytes
packing has been shown to give rise to a concomitant increase in
the size of corneocytes gaps and this was thought to enhance percu-
taneous penetration [42,43]. Hence, the shrinkage of the corneocytes
due to the application of hypobaric pressure was considered to be
the reason for the 4 kDa dextran entering the skin more easily via
non-follicular routes [44,45].
Fig. 5. Porcine and rat skin histology a), e) and b), f) control under atmospheric conditions 4 × and 40 × respectively c) and d) porcine skin after hypobaric treatment of 500mBar for 7 h at
4 × and 40 × respectively g) and h) rat skin after hypobaric treatment of 500mBar for 1 h at 4 × and 40 × respectively. SC, stratum corneum, E, epidermis, D, dermis and arrow indicates
dermal–epidermal detachment.
72 R. Inacio et al. / Journal of Controlled Release 226 (2016) 66–76
The hypobaric stressed porcine skin was found to be signiﬁcantly
thinner at the end of the transport studies. A skin thickness of 0.89 ±
0.1 mm upon the application of hypobaric treatment vs. 1.1 ± 0.1 mm
under atmospheric pressure conditions was registered (p b 0.05, n =
5). Conversely, when rat skinwas treatedwith the same hypobaric con-
ditions used in the in vitro permeation studies and subsequent in vivo
experiments therewas no signiﬁcant alteration (p N 0.05) inmembrane
thickness (Supplementary data Fig. S3). Skin thinning upon the applica-
tion of hypobaric stress has been previously reported in the literature
[46], but as the rat skin did not show a signiﬁcant thinning effect in
this study it was not thought to be a major contributor to the enhanced
percutaneous penetration induced by the application of hypobaric
pressure.
Light microscopy was used to visualize the histological changes to
porcine and rat skin upon hypobaric treatment. Dermal–epidermal
detachment was observed in few localized areas of both porcine (Fig.
5c) and rat skin samples (Fig. 5g). However, the majority of the skin
maintained its morphological and structural characteristics (Fig. 5d
and h) when compared to the control samples (Fig. 5b and f). Minor
changes were observed in cell cohesion, with some areas of the stratum
corneum detaching or peeling off from the adjacent layer. However, this
wasmost probably due to sample handling since this was also observed
in the control skin samples.
Such a small amount of dermal–epidermal detachmentwas thought
unlikely to inﬂuence drug delivery via the skin as the stratum corneum
seemed to remain intact upon hypobaric driven delivery. Previous
in vivo work in human subjects has shown a rapid repair of the der-
mal–epidermal adherence after 2 h of hypobaric treatment [47,48].
This process was also observed in porcine and rat animal models [49,
50]. The data generated in the current work suggested that the
Fig. 6.Hypobaric stress induced vascular response a) representative % change in contralateral and ipsilateral (control) hind paw blood ﬂow from baseline over a 15 min period following
hypobaric stress treatment b) % change in contralateral and ipsilateral (control) paw blood ﬂow from baseline 3min after hypobaric treatment (maximumvasodilatation). Student's t-test
with ***p b 0.001 c) representative full-ﬁeld laser perfusion imaging pictures alongside grey scale picture showing blood ﬂow at baseline, 2 and 15min after hypobaric stress treatment of
the contralateral hind paw. Arrow indicates the site of topical hypobaric treatment.
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enhanced permeation in response to hypobaric stress was not a conse-
quence of skin damage.
3.2. In vivo studies
3.2.1. Blood ﬂow
The hemodynamic response immediately after the application of
hypobaric pressure resulted in a signiﬁcant increase in blood ﬂow
(p b 0.001). This effected started to diminish at ca. 5 min, which was
in good agreement with previously reported maximum hemodynamic
response period under hypobaric stress [14] (Fig. 6a). Themaximumva-
sodilation was observed between 0 to 3 min following application of
sub-atmospheric pressure to the contralateral hind paw (Fig. 6b and
c). This response was signiﬁcantly greater (p N 0.05) with a 42.3 ±
8.5% increase in the contralateral hind paw blood ﬂow upon hypobaric
treatment, when compared to the control (Fig. 6c). The increase in
cutaneous blood ﬂow upon the application of sub-atmospheric pres-
sures was attributed to a pressure gradient between the surrounding
tissues and the site of topical mechanical stress [51,52].
3.2.2. Pharmacokinetic studies
The FD-10S was selected as themodel macromolecule for the in vivo
percutaneous studies since the results from the in vitro data showed
that the larger molecule was enhanced to a greater extent by hypobaric
pressure. In vivo, the topical application of local hypobaric stress result-
ed in a rapid appearance of the dextran in the systemic circulation after
1 h (Fig. 7, 7.2± 2.81 fg·mL−1). However, as the systemic levels of dex-
tran for the remainder of the time coursewere found to be too low to be
accurately quantiﬁed by liquid scintillation counting, parameters such
as Cmax and Tmax could not be derived.
The in vivo transdermal delivery enhancement of the FD-10S upon
the application of topical hypobaric stress appeared to accord with the
in vitro skin characterization results. It was notable that the permeation
was only enhanced during the application of the hypobaric stimuli. This
concurred with the hypothesis that the hypobaric pressure was tempo-
rally opening the follicular route for this molecule to penetrate into the
skin. This follicular opening appeared to quickly reverse when the skin
stretching was terminated upon the return to normal pressure condi-
tions and therefore this method of percutaneous penetration enhance-
ment could be considered as being reversible, i.e., it did not damage
the barrier properties of the skin.
The cutaneous deposition proﬁle of dextran supported the pharma-
cokinetic analysis and the previous in vitro studies. Drug depositionwas
found to be signiﬁcantly greater (p b 0.01, data not displayed graphical-
ly) under hypobaric pressure conditions in each layer of the skin, but
this effect was more pronounced upon dextran localization in deeper
skin tissues. The amount of dextran found in the stratum corneum and
dermal tissue was 4.3 and 5.7-fold higher, respectively (data not
shown graphically).
In vivo transdermal delivery was found to be signiﬁcantly higher
(p b 0.001) when compared to that observed in vitro (Fig. 8a) and it re-
sulted in a 13-fold increase in the amount of drug that permeated
through the skin when the cutaneous microcirculation was present de-
spite. This was unusual because the skin barrier is commonly thought to
be more permeable when tested in vitro [18]. The enhanced in vivo up-
take was thought to be as result of the signiﬁcant effect of the skin mi-
crocirculation on the uptake of the dextran. This result was therefore
considered as evidence to suggest that in addition to the hypobaric pres-
sure opening the follicular pathway in the skin the increase in cutaneous
blood ﬂow had a signiﬁcant role on enhancing macromolecule deposi-
tion in the cutaneous tissue. This hypothesis accords with previous
Fig. 7. Blood concentration vs. time proﬁle of 14C-labeled 10 kDa dextran in phosphate
buffer (0.79 μCi equivalent to 1.428 pM) applied topically under atmospheric
(1010 mBar) and hypobaric conditions (500 mBar). Each point represents mean ±
standard deviation (n = 5). #Values below limit of detection (b3 × background level
measurements).
Fig. 8. in vivo percutaneous penetration studies under atmospheric (1010 mBar) and hypobaric (500 mBar) pressure conditions. a) in vitro vs. in vivo 10 kDa dextran rat skin deposition
b) biodistribution of 14C labeled 10kDa dextran. Eachpoint representsmean±standarddeviation (n=5). ER (Enhancement ratio) represents the ratio between the amount of drug found
under hypobaric and atmospheric conditions. Students t-test with *p b 0.05, **p b 0.01 and ***p b 0.001.
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work,which suggested that an enhanced blood ﬂowallowed deeper tis-
sue distribution of topically applied agents [53–55]. There could have
been some synergy between the follicular transport enhancement and
the increase in blood ﬂow because the follicular structures are heavily
vascularised, but this could not be conﬁrmed with the current data set
[56,57]. Organ uptake of the 14C-labeled 10 kDa dextran following top-
ical delivery (Fig. 8b) supported the blood sampling and cutaneous tis-
sue results in that it showed higher levels upon the application of
hypobaric stress. A greater tissue uptake (p b 0.05) under hypobaric
driven delivery was observed in all the collected organs, which was
thought to be attributable to a greater dextran uptake into the systemic
circulation induced by the pressure applied to the skin surface. The dis-
tribution of the dextran was consistent with its high molecular weight
and this provided support for the earlier suggestion that the molecule
had not been chemically modiﬁed during the delivery process.
4. Conclusions
The application of local hypobaric stress appears to be simple yet
effectivemethod to increase the percutaneous penetration of topically ap-
plied macromolecules. In this study the pressure was applied to the skin
using a depressurised chamber that created an airtight seal with the sur-
face of the skin and this same technique could be applied to humans by
trained medical professionals. However, some development of the appli-
cation device would be needed to make it portable and thus suitable for
home use if this was required. The application of hypobaric stress causes
a series of changes to the skin, but considering both the spectroscopic data
and the transport data the two most signiﬁcant effects of local pressure
appeared to be the increase in blood ﬂow and the enlargement of the fol-
licular infundibula. In combination, these two effects seemed to promote
the transport of dextranmolecules into the skin and their passage into the
systemic circulation. Themaximum size of dextran used in this studywas
10,000 Mw and therefore the maximum size of molecule that hypobaric
pressure could drive into the skin is unknown. Further work is needed
to understand if hypobaric stress could deliver larger molecules such as
vaccines into the skin and to validate this penetration enhancement tech-
nique in man. In addition, the skin's response to repeated application of
hypobaric stress should be assessed in vivo if this novel technology is to
be used in the treatment of chronic conditions.
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